General
Preferred name
FLUPHENAZINE
Synonyms
FLUPHENAZINE HYDROCHLORIDE ()
FLUPHENAZINE DECANOATE ()
FLUPHENAZINE DIHYDROCHLORIDE ()
Prolixin ()
Permitil ()
Moditen ()
Fluphenazine (HCl) ()
Fluphenazine (dihydrochloride) ()
Fluphenazine (hydrochloride) ()
NSC-179197 ()
Anatensol ()
Fluphenazine HCl ()
SQUIBB 4918 ()
Fluphenazine dihydrochloride ()
Dapotum ()
Fluphenazini hydrochloridum ()
Flufenazina ()
NSC-62323 ()
Fluphenazine ()
P&D ID
PD009883
CAS
146-56-5
69-23-8
47646-09-3
Tags
available
drug
nuisance
Approved by
FDA
First approval
1959
Drug indication
Psychotic disorder
Middle East Respiratory Syndrome (MERS)
Multiple myeloma
Severe acute respiratory syndrome (SARS)
Psychotic disorders
Psychosis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE
29
DESCRIPTION
Fluphenazine belongs to the family of phenothiazine anti-psychotic drugs.
(GtoPdb)
DESCRIPTION
Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2[1][2][3][4][6].
DESCRIPTION
Dopamine receptor antagonist; antipsychotic
(LOPAC library)
DESCRIPTION
Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor. It also inhibits Histamine H1 Receptor.
(Enamine Bioactive Compounds)
DESCRIPTION
Fluphenazine dihydrochloride (Prolixin) is an inhibitor of phenothiazine-class D1DR and D2DR; In studies, Fluphenazine can be used to probe the effects and metabolic process of this commonly used dopamine antagonist.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
5
Organisms
6
Compound Sets
27
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
72
Molecular Weight
437.17
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
2
cLogP
4.31
TPSA
29.95
Fraction CSP3
0.45
Chiral centers
0.0
Largest ring
6.0
QED
0.73
Structural alerts
1
CAD
Nuisance compounds
Related compounds
Custom attributes
(extracted from source data)
Target
Dopamine Receptor
SARS-CoV
Sodium Channel
dopamine
CALM1, DRD1, DRD2, DRD5, HRH1, HTR2A, HTR6, HTR7
Selectivity
D1/D2
Indication
schizophrenia
MOA
Dopamine Receptor antagonist
Therapeutic Class
Antipsychotic Agents
Antiviral Agents
Pathway
Anti-infection
GPCR/G protein
Membrane Transporter/Ion Channel
Neuronal Signaling
Neuroscience
Source data
